An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
The healthcare gurus known as the Baker Brothers have amassed a huge position in the orphan drugmaker Synageva BioPharma Corp. Should investors follow in their footsteps?
5 Things Johnson & Johnson's Management Wants You to Know
Since earnings reports only scratch the surface of how a company is performing, we decided to take a deeper dive into what Johnson & Johnson's management had to say about its latest quarter. Here are the five most important things you need to know as an investor.